TRACON - TCON Amount of Long-Term Liabilities

Brandmark of TRACON (TCON)

TRACON Pharmaceuticals (TCON) is developing advanced envafolimab antibodies to combat sarcoma and building IT systems for clinics, as reflected in this price chart. The company replenishes its capital through royalties and upfront payments from targeted therapy partners. However, the business is currently undergoing restructuring without a stable cash inflow, and long-term debt stands at 0.00, with the structure relying on existing cash reserves.

TCON - TRACON Pharmaceuticals Company Long-Term Debts over the range 07/04/2022 - 08/04/2024

Summary analytical data breakdowns for TRACON (TCON)

- market price and analyst price targets:
Stock Price traconpharma.com|TCON - Consensus Target
- issuer market value details:
Market Value TRACON Pharmaceuticals|TCON - Total Company Value
- issuer book value statistics:
Accounting Value of a Share TRACON Pharmaceuticals|TCON - Book Capitalization|Market Capitalization to Book Value Ratio traconpharma.com|TCON - Company Total Assets
- debt level and financial liquidity data:
Total Debt to Equity Ratio TRACON Pharmaceuticals|TCON - Long-Term Debt to Equity|Current Liabilities to Capital TRACON Pharmaceuticals, Inc|TCON - Company Debts|Debt to Book Value Ratio TRACON Pharmaceuticals|TCON - Company Long-Term Liabilities|Company Short-Term Loans and Borrowings TRACON Pharmaceuticals|Critical Liquidity Ratio traconpharma.com
- earnings and market ratios statistics:
TCON - Net Profit
Analysis of all company metrics:traconpharma.com - TCON
Mass-produced product of TRACON Pharmaceuticals, Inc.

This metric aggregates all liabilities with maturities exceeding twelve months, reflecting the long-term debt load. This metric determines financial stability and the business's ability to service major loans. For TRACON Pharmaceuticals (TCON), such funds are critical for maintaining a highly qualified staff of oncologists and biologists. Investments in scientific capital require stable financing. By analyzing the company's long-term debt chart, an investor assesses the balance between borrowed capital and research development.

Competitor analysis for TRACON Pharmaceuticals

Company Long-Term Debts Tempus Labs TEM|QGEN: Company Long-Term Liabilities|Ionis Pharmaceuticals, Inc. - Amount of Long-Term Liabilities|Repligen Corp. (RGEN) - Company Long-Term Debt|Avidity Corp - Company Long-Term Loans and Borrowings|CRSP (CRISPR Therapeutics AG) - Company Long-Term Debts|Company Long-Term Debts genedx.com|Company Long-Term Debts RARE|Company Long-Term Liabilities Beam Therapeutics Inc BEAM|Company Long-Term Debt Sarepta Therapeutics Inc SRPT|Twist Bioscience Corp (TWST) - Long-Term Debt|TXG - Company Long-Term Debt|NTLA (intelliatx.com) - Company Long-Term Indebtedness|STOK (Stoke Therapeutics, Inc.) - Company Long-Term Liabilities|BioLife Solutions Inc - Company Long-Term Loans and Borrowings|Company Long-Term Debt Wave Life Sciences Corp|Maze Therapeutics Corp - Long-Term Liabilities|Company Long-Term Debts SION|PRME (primemedicine.com) - Company Long-Term Loans and Borrowings|Company Long-Term Debts TSHA (Taysha Gene Therapies, Inc.)|Company Long-Term Debts uniQure NV QURE|MGTX - Company Long-Term Debt|Company Long-Term Loans and Borrowings RGNX (REGENXBIO Corp)|Solid Biosciences Inc. (SLDB) - Company Long-Term Debt|Company Long-Term Liabilities ocugen.com|PACB (PacBio) - Company Long-Term Debts|Company Long-Term Debts Benitec Biopharma Inc|Company Long-Term Debts DSGN|Company Long-Term Liabilities Rocket Corp RCKT|Company Long-Term Debts FDMT (4D Molecular Therapeutics)|Lexeo Therapeutics Inc. (LXEO) - Long-Term Debt|KRRO: Company Long-Term Liabilities|EDIT - Company Long-Term Debts|SLN (Silence Therapeutics Inc.) - Company Long-Term Liabilities|PRQR: Amount of Long-Term Liabilities|CDXS (Codexis Inc) - Company Long-Term Debts|sangamo.com (SGMO) - Long-Term Debt Volume|Company Long-Term Debts NAUT|Company Long-Term Liabilities Metagenomi Inc. MGX|Company Long-Term Debts DTIL (Precision BioSciences)|Company Long-Term Debts Generation Bio Co GBIO|BOLD - Company Long-Term Debt|XCUR: Company Long-Term Debt|imunon.com (IMNN) - Company Long-Term Debt|PHIO - Long-Term Debt Volume|Company Long-Term Liabilities MBIO|RNAZ (TransCode) - Amount of Long-Term Liabilities|Company Long-Term Debts BNGO|Company Long-Term Liabilities adnas.com APDN|Company Long-Term Debt bluebird bio BLUE|ImmunoPrecise Antibodies Ltd (IPA) - Long-Term Debt|OMGA - Company Long-Term Debt|OMIC (Singular Genomics Corp) - Company Long-Term Indebtedness|RGLS: Company Long-Term Debts|Company Long-Term Indebtedness SYRS|Company Long-Term Debt Telesis Bio|Company Long-Term Indebtedness UBX (Unity Biotechnology Inc.)